Declan T Barry1, Mark Beitel2, Christopher J Cutter2, David A Fiellin3, Robert D Kerns4, Brent A Moore4, Lindsay Oberleitner2, Lynn M Madden2, Christopher Liong5, Joel Ginn5, Richard S Schottenfeld6. 1. Yale School of Medicine, Department of Psychiatry, New Haven, CT, 06511, United States; APT Foundation Pain Treatment Services, New Haven, CT, 06519, United States. Electronic address: declan.barry@yale.edu. 2. Yale School of Medicine, Department of Psychiatry, New Haven, CT, 06511, United States; APT Foundation Pain Treatment Services, New Haven, CT, 06519, United States. 3. Yale School of Medicine, Department of Internal Medicine, New Haven, CT, 06519, United States. 4. Yale School of Medicine, Department of Psychiatry, New Haven, CT, 06511, United States; VA Connecticut Healthcare System, West Haven, CT, 06516, United States. 5. APT Foundation Pain Treatment Services, New Haven, CT, 06519, United States. 6. Yale School of Medicine, Department of Psychiatry, New Haven, CT, 06511, United States.
Abstract
AIMS: The primary study aim was to evaluate the feasibility and acceptability of cognitive-behavioral therapy (CBT) for opioid use disorder and chronic pain. The secondary aim was to examine its preliminary efficacy. METHODS: In a 12-week pilot randomized clinical trial, 40 methadone-maintained patients were assigned to receive weekly manualized CBT (n = 21) or Methadone Drug Counseling (MDC) to approximate usual drug counseling (n = 19). RESULTS:Twenty of 21 patients assigned to CBT and 18 of 19 assigned to MDC completed the pilot study. Mean (SD) sessions attended were 8.4 (2.9) for CBT (out of 12 possible) and 3.8 (1.1) for MDC (out of 4 possible); mean (SD) patient satisfaction ratings (scored on 1-7 Likert-type scales) were 6.6 (0.5) for CBT and 6.0 (0.4) for MDC (p < .001). The proportion of patients abstinent during the baseline and each successive 4-week interval was higher for patients assigned to CBT than for those assigned to MDC [Wald χ2 (1) = 5.47, p = .02]; time effects (p = .69) and interaction effects between treatment condition and time (p = .10) were not significant. Rates of clinically significant change from baseline to end of treatment on pain interference (42.9% vs. 42.1%, [χ2 (1, N = 40) = 0.002, p = 0.96]) did not differ significantly for patients assigned to CBT or MDC. CONCLUSIONS: We found support for the feasibility, acceptability, and preliminary efficacy of cognitive-behavioral therapy relative to standard drug counseling in promoting abstinence from nonmedical opioid use among patients with opioid use disorder and chronic pain. Overall, patients exhibited improved pain outcomes, but these improvements did not differ significantly by treatment condition.
RCT Entities:
AIMS: The primary study aim was to evaluate the feasibility and acceptability of cognitive-behavioral therapy (CBT) for opioid use disorder and chronic pain. The secondary aim was to examine its preliminary efficacy. METHODS: In a 12-week pilot randomized clinical trial, 40 methadone-maintained patients were assigned to receive weekly manualized CBT (n = 21) or Methadone Drug Counseling (MDC) to approximate usual drug counseling (n = 19). RESULTS: Twenty of 21 patients assigned to CBT and 18 of 19 assigned to MDC completed the pilot study. Mean (SD) sessions attended were 8.4 (2.9) for CBT (out of 12 possible) and 3.8 (1.1) for MDC (out of 4 possible); mean (SD) patient satisfaction ratings (scored on 1-7 Likert-type scales) were 6.6 (0.5) for CBT and 6.0 (0.4) for MDC (p < .001). The proportion of patients abstinent during the baseline and each successive 4-week interval was higher for patients assigned to CBT than for those assigned to MDC [Wald χ2 (1) = 5.47, p = .02]; time effects (p = .69) and interaction effects between treatment condition and time (p = .10) were not significant. Rates of clinically significant change from baseline to end of treatment on pain interference (42.9% vs. 42.1%, [χ2 (1, N = 40) = 0.002, p = 0.96]) did not differ significantly for patients assigned to CBT or MDC. CONCLUSIONS: We found support for the feasibility, acceptability, and preliminary efficacy of cognitive-behavioral therapy relative to standard drug counseling in promoting abstinence from nonmedical opioid use among patients with opioid use disorder and chronic pain. Overall, patients exhibited improved pain outcomes, but these improvements did not differ significantly by treatment condition.
Authors: C Hendricks Brown; Wei Wang; Sheppard G Kellam; Bengt O Muthén; Hanno Petras; Peter Toyinbo; Jeanne Poduska; Nicholas Ialongo; Peter A Wyman; Patricia Chamberlain; Zili Sloboda; David P MacKinnon; Amy Windham Journal: Drug Alcohol Depend Date: 2008-01-22 Impact factor: 4.492
Authors: Mark A Ilgen; Amy S B Bohnert; Stephen Chermack; Carly Conran; Mary Jannausch; Jodie Trafton; Frederic C Blow Journal: Addiction Date: 2016-04-15 Impact factor: 6.526
Authors: Robert H Dworkin; Dennis C Turk; Kathleen W Wyrwich; Dorcas Beaton; Charles S Cleeland; John T Farrar; Jennifer A Haythornthwaite; Mark P Jensen; Robert D Kerns; Deborah N Ader; Nancy Brandenburg; Laurie B Burke; David Cella; Julie Chandler; Penny Cowan; Rozalina Dimitrova; Raymond Dionne; Sharon Hertz; Alejandro R Jadad; Nathaniel P Katz; Henrik Kehlet; Lynn D Kramer; Donald C Manning; Cynthia McCormick; Michael P McDermott; Henry J McQuay; Sanjay Patel; Linda Porter; Steve Quessy; Bob A Rappaport; Christine Rauschkolb; Dennis A Revicki; Margaret Rothman; Kenneth E Schmader; Brett R Stacey; Joseph W Stauffer; Thorsten von Stein; Richard E White; James Witter; Stojan Zavisic Journal: J Pain Date: 2007-12-11 Impact factor: 5.820
Authors: Kevin E Vowles; Katie Witkiewitz; Karen J Cusack; Wesley P Gilliam; Karen E Cardon; Sarah Bowen; Karlyn A Edwards; Mindy L McEntee; Robert W Bailey Journal: J Pain Date: 2019-11-21 Impact factor: 5.820
Authors: Erin Ferguson; Emily Zale; Joseph Ditre; Danielle Wesolowicz; Bethany Stennett; Michael Robinson; Jeff Boissoneault Journal: Ann Behav Med Date: 2021-05-06
Authors: Kristen P Morie; Marc N Potenza; Mark Beitel; Lindsay M Oberleitner; Corey R Roos; Sarah W Yip; David E Oberleitner; Marina Gaeta; Declan T Barry Journal: Drug Alcohol Depend Date: 2020-10-24 Impact factor: 4.492
Authors: Patrick H Finan; Janelle Letzen; David H Epstein; Chung Jung Mun; Samuel Stull; William J Kowalczyk; Daniel Agage; Karran A Phillips; Diego A Pizzagalli; Kenzie L Preston Journal: Pain Med Date: 2021-09-08 Impact factor: 3.750
Authors: Kimberly A DiMeola; Jeff Haynes; Meredith Barone; Mark Beitel; Lynn M Madden; Christopher J Cutter; Anthony Raso; Marina Gaeta; Xiaoying Zheng; Declan T Barry Journal: J Addict Med Date: 2022 Mar-Apr 01 Impact factor: 3.702
Authors: William C Becker; Erin E Krebs; Sara N Edmond; Lewei A Lin; Mark D Sullivan; Roger D Weiss; Adam J Gordon Journal: J Gen Intern Med Date: 2020-11-03 Impact factor: 5.128